Abstract: A method of treating root avulsion injury in a subject in need thereof includes administering to the subject a therapeutic agent that inhibits one or more of catalytic activity, signaling, and function of PTP?.

Abstract: The invention relates a pharmaceutical composition containing botulinum toxin and a mucopolysaccharide uses thereof with increased pharmacological activity and long lasting botulinum toxin effect.

Abstract: The present invention relates to nanoparticles comprising aminoacyl tRNA synthetase and an anticancer composition comprising the same and, specifically, to nanoparticles which comprise glycyl-tRNA synthetase (GRS), leucyl-tRNA synthetase (LRS), and isoleucyl-tRNA synthetase (IRS), and have anticancer or immunostimulating activity; a pharmaceutical composition for preventing or treating cancer, comprising the nanoparticles as an active ingredient; a composition for immunostimulation; and a method for preparing the nanoparticles.

Abstract: The invention relates to methods of treatment of medical conditions (e.g., diseases and injuries) in a mammal (e.g., a human), such as hypoxia/ischemia, burns, and viral infections (e.g., influenza, West Nile virus, and Dengue fever), in adults and in children (e.g., neonates) by administering a composition that includes an IAIP.

Abstract: We provide a polypeptide vaccine for treatment and prevention of cancer, particularly prevention of metastasis of cancer. Also provided are methods of treating or preventing cancer, and pharmaceutical compositions comprising the polypeptide vaccine.

Abstract: The present invention comprises compositions, methods, and devices for creating an infection-mimicking environment within a polymer scaffold to stimulate antigen-specific dendritic cell activation. Devices of the present invention are used to provide protective immunity to subjects against infection and cancer.

Abstract: The present invention relates to the field of prophylaxis and therapy of cancer. In particular there is provided a protein Indoleamine 2,3-dioxygenase (IDO) or peptide fragments here of that are capable of eliciting anti-cancer immune responses. Specifically, the invention relates to the use of IDO or peptides derived here from or IDO specific T-cells for treatment of cancer. The invention thus relates to an anti-cancer vaccine which optionally may be used in combination with other immunotherapies and to IDO specific T-cells adoptively transferred or induced in vivo by vaccination as a treatment of cancer. It is an aspect of the invention that the medicaments herein provided may be used in combination with cancer chemotherapy treatment. A further aspect relates to the prophylaxis and therapy of infections by the same means as described above. The use of IDO and immunogenic peptide fragments hereof in cancer and infection treatment, diagnosis and prognosis is also provided.

Abstract: The present invention provides methods of treating, protecting against and inducing an immune response against a tumor or cancer, comprising the step of administering to a subject a recombinant Listeria strain. In one embodiment the present invention relates to a recombinant Listeria strain, said recombinant Listeria strain comprising a recombinant nucleic add, said nucleic add comprising a first open reading frame encoding a recombinant polypeptide comprising a first N-terminal fragment of an LLO protein fused to a heterologous antigen or fragment thereof, and wherein said recombinant nucleic add further comprises a second open reading frame encoding a mutant PrfA protein.

Abstract: The present application provides a vaccine composition comprising: bacteria engineered to express at least one N-glycan of Campylobacter, such as C. jejuni for example, or an N-glycan derivative thereof on its cell surface; and one or more of a physiologically acceptable diluent, excipient, adjuvant or carrier. The bacteria is Escherichia coli, Salmonella or any suitable bacteria that offers sufficient expression and improved immunogenic response. The vaccine composition can be formulated for administration to animals, such as poultry, including chickens.

Abstract: A mutated Bordetella strain comprising at least a mutated ptx gene, a deleted or mutated dnt gene and a heterologous ampG gene is provided. The attenuated mutated Bordetella strain can be used in an immunogenic composition or a vaccine for the treatment or prevention of a Bordetella infection. Use of the attenuated Bordetella strain for the manufacture of a vaccine or immunogenic composition, as well as methods for protecting mammals against infection by Bordetella are also provided.

Abstract: The invention provides vectors, attenuated pathogens, compositions, methods, and kits for use in preventing or treating infection by an infectious pathogen, especially Chlamydia trachomatis. The vectors comprise the plasmid encoded ppg genes from Chlamydia, ppg1, ppg2, ppg3, ppg5, ppg6, ppg7 and/or ppg8, but lack ppg4, a regulator of virulence associated genes. The application also provides attenuated pathogens, especially chlamydia, which are cured of their plasmid and have additional mutations to improve the attenuation, especially mutations in the CT135 gene or in the tryptophan operon (trp promoter, trpA, or trpB). Uses of said nucleic acids and attenuated pathogens for inducing or modulating an immune response in a subject, especially for prevention or treatment of infections, are proposed.

Abstract: Disclosed herein are single nucleic acid constructs comprising a vector, wherein the vector comprises: a first nucleic acid sequence, wherein the first nucleic acid sequence comprises one or more antigenic sequences of interest, one or more spacer sequences and one or more hydrophobic anchor sequences, operably linked to a first transcriptional control element; a second nucleic acid sequence, wherein the second nucleic acid sequence comprises one or more pathogen-associated molecular pattern (PAMP) sequences operably linked to a second transcriptional control element; a third nucleic acid sequence, wherein the third nucleic acid sequence comprises one or more cell surface receptor binding sequences operably linked to a third transcriptional control element; and a selectable marker. Also described herein, are methods of making the single nucleic acid constructs and methods of administering the single nucleic acid constructs for the treatment or prevention of infections and cancer.

Abstract: The present invention relates to novel CD4+ and CD8+ T cell epitopes that are specific for HPV-specific E6 and E7 oncoproteins, to peptides comprising these novel T cell epitopes, and to (vaccine) compositions comprising these peptides for use in methods for the prevention and/or treatment of HPV related diseases. Preferred epitopes are recognized by a T cell that infiltrates a cervical neoplastic lesion or by a T cell from a draining lymph node, and are presented by an HLA-DQ or HLA-DP molecule, or an HLA-B.

Abstract: The invention is directed to a vaccine comprising: i) coxsackie B virus CBV1 and CBV2, and ii) at least one coxsackie B virus selected from CBV3, CBV4, CBV5 and CBV6. The CBVs are present in the vaccine in inactivated form, in the form of a component of the virus or as an antibody against the virus. The vaccine is effective in preventing and treating type 1 diabetes. So is an anti-coxsackie B virus composition provided.

Abstract: The subject invention pertains to isolated influenza virus that is capable of infecting canids and causing respiratory disease in the canid. The subject invention also pertains to compositions and methods for inducing an immune response against an influenza virus of the present invention. The subject invention also pertains to compositions and methods for identifying a virus of the invention and diagnosing infection of an animal with a virus of the invention.

Abstract: The present invention relates to methods for obtaining a whole virus vaccine candidate stock. The present invention also relates to an inactivated whole virus vaccine candidate stock that can be used for vaccination purposes as well as development of novel high titer virus, which is the preferred virus for this technique.

Abstract: Adjuvants comprising chitosan cross-linked with an aldehyde or mannosylated chitosan are provided herein. Methods of making the adjuvants and methods of combining or linking the adjuvants with antigens are also provided. The adjuvant-antigen combinations can be used in vaccine formulations and the vaccine formulations can be used in methods to vaccinate animals against the source of the antigen or to enhance the immune response in a subject.

Abstract: The present invention relates to a stable liquid formulation of etanercept (recombinant p75 sTNFR:Fc fusion protein), and more particularly, to a liquid formulation comprising one or more stabilizers selected from the group consisting of methionine, lysine, histidine, and pharmaceutically acceptable salts thereof in an amount sufficient to reduce by-product formation of etanercept during storage. The liquid formulation according to the present invention effectively reduces production of etanercept by-products and to stably maintain its pharmaceutical efficacies for long-term storage. Therefore, the reconstitution procedure is not required before administration, and the sterile formulation can be administered to patients to ensure patient safety. Thus, it can be applied to the fields in need of etanercept treatment.

Abstract: The present invention is directed to new 5-ALA derivatives, particles and formulation thereof, related methods of preparation and methods of use thereof. In particular, the invention relates to compounds of the invention, particles and formulation thereof useful in the treatment of a cancer and/or the diagnosis of a cancer cell such as in photodynamic therapy or photodynamic diagnosis.

Abstract: The present invention includes compositions and methods for preventing one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns caused by an active agent or a drug in a human or animal subject comprising: an amount of a lysophosphatidyl compound adapted for oral administration effective to reduce or prevent one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns caused by the active agent or drug. Such compositions may further comprise a monoglyceride, a free fatty acid or a combination of the foregoing, including, e.g., a eutectic mixture.

Abstract: The present invention concerns an oral pharmaceutical formulation made from a microemulsion between an aqueous solution comprising at least one BCS (Biopharmaceutics Classification System) class III active principle and one oily phase comprising an oily vehicle that is self-emulsifiable on contact with water.

Abstract: Disclosed is a pharmaceutical composition in the form of a tablet suitable for dissolution in the buccal cavity, said composition comprising i) an effective amount of a narcotic active ingredient, and ii) a pharmaceutically acceptable amine having a pK of about 8 or greater, wherein the molar ratio of amine:active ingredient is at least about 5:1.

Abstract: Provided is a skin external preparation including a drug and nanometer-size molecular assemblies. The molecular assemblies contain an amphiphilic block copolymer having a hydrophilic block chain including a sarcosine-derived structural unit and a hydrophobic block chain including a hydroxy acid-derived structural unit. The skin external preparation according to the present invention may reduce skin irritation caused by the drug, be very safe, and have excellent pharmacological effects, even when a drug that is generally difficult to be transdermally administered due to its strong skin irritation is contained therein.

Abstract: Methods and reagents for enhancing cellular uptake of a cargo molecule by covalently bonding optionally-substituted fluorenyl groups to the cargo molecules, where cellular uptake includes at least partial uptake into the cytosol. Useful fluorenylation reagents include those of formula: and salts thereof where variables are as defined. Cargo molecules include peptides and proteins. Also provided are fluorenylated cargo molecules, including fluorenylated peptides and proteins.

Abstract: The presently described technology provides compositions comprising aryl carboxylic acids chemically conjugated to hydromorphone (4,5-?-epoxy-3-hydroxy-17-methyl morphinan-6-one) to form novel prodrugs/compositions of hydromorphone. The hydromorphone prodrugs of the present technology have decreased side effects and decreased potential for abuse compared to unconjugated hydromorphone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.

Abstract: Compositions are described for direct protein delivery into multiple cell types in the mammalian inner ear. The compositions are used to deliver protein(s) (such as gene editing factors) editing of genetic mutations associated with deafness or associated disorders thereof. The delivery of genome editing proteins for gene editing and correction of genetic mutations protect or restore hearing from genetic deafness. Methods of treatment include the intracellular delivery of these molecules to a specific therapeutic target.

Abstract: The present disclosure provides, inter alia, formulation compositions comprising modified nucleic acid molecules which may encode a protein, a protein precursor, or a partially or fully processed form of the protein or a protein precursor. The formulation composition may further include a modified nucleic acid molecule and a delivery agent. The present invention further provides nucleic acids useful for encoding polypeptides capable of modulating a cell's function and/or activity.

Abstract: The present application relates to the molecular labeling and in vivo imaging of amyloids. Specifically, the present application relates to a polypeptide-based method/vector for targeting amyloids. Such a method/vector enables the transportation of compounds or drugs across blood-brain-barrier of an individual and then binding to amyloids in brain. Particularly, the vector of the present application can transport an imaging group linked to the vector across the blood-brain-barrier, and can binds to amyloids in brain, and thus enables the labeling and imaging of amyloid deposits. When used as an imaging agent for detecting amyloid deposits in body or tissues, the vector may be labeled with suitable optical imaging groups, radioactive isotopes or imaging groups suitable for MRI or CT detection.

Abstract: Provided herein are methods of enhancing in vivo efficacy of an active agent, comprising: administering to a subject an active agent that is coupled to a bioelastic polymer or elastin-like peptide, wherein the in vivo efficacy of the active agent is enhanced as compared to the same active agent when administered to the subject not coupled to (or not associated with) a bioelastic polymer or ELP.

Abstract: Disclosed is a compound of formula (I): wherein L, R1-R5, A, B, M, and n are as defined in the specification, as well as a method of preparing the compound. Also disclosed are a method of blood-pool imaging in a mammal and a method of imaging a lymph node in a mammal, comprising use of the compound.

Abstract: A water-absorbent carrier for moist heat sterilization can be used in a narrow space and does not have a risk of generating foreign matter. The water-absorbent carrier is obtained by embedding a water-absorbent substance in a synthetic resin. The water-absorbent carrier can be manufactured by impregnating the water-absorbent substance with a water-soluble substance, drying the water-absorbent substance, embedding the water-absorbent substance in a thermoplastic synthetic resin, and washing the water-absorbent substance to remove the water-soluble substance. Alternatively, the water-absorbent carrier can be manufactured by dispersing a water-insoluble synthetic resin in a dispersion medium, mixing the water-absorbent substance in the dispersion medium, pouring the mixture into a mold, and volatilizing the dispersion medium. A medical article to be sterilized includes the water-absorbent carrier packaged in a closed space.

Abstract: The invention relates to a device for treating soil with electromagnetic radiation, comprising: a magnetron antenna (9) for generating microwave radiation with a relatively high frequency; a wave guide (16) connected to the output of the magnetron antenna (9); downward directed tubular members (18, 19) connected to the wave guide (16); a manifold (17) arranged between the two tubular members (18, 19) and the wave guide (16); a tuner unit (26) arranged on the wave guide (16); and cooling means (22, 22?, 22?) for cooling the electromagnetic radiation reflected by the soil. The invention also relates to a cable (24) provided with a single high-voltage cable and one or more low-voltage cables and/or a number of optical cables which are arranged in a shared cable.

Abstract: The invention relates to a sterilizers and methods of sterilization of an instrument. The sterilizer includes an ozone generator, an air mover, an oxygen concentrator, and a controller. The ozone generator, which is housed by the sterilization chamber, generates at least one plasma field. The air mover circulates air through the sterilization chamber. The oxygen concentrator delivers oxygen-concentrated air to the sterilization chamber. The controller communicates with the ozone generator, the air mover, and the oxygen concentrator. The sterilizer may also include a battery to power the components of the sterilizer. A portable case may house the sterilizer.

Abstract: The sanitizing device for tool and cart handles is designed to rest on a base mount attached to the tool handle. When the user wants to use the sanitizing device they move the device from its rest position, spray sanitizing solution onto the desired surface area of the tool or cart handle, then slide the device along the handle to sanitize and/or disinfect it. The device includes a sponge which aids in the thorough sanitization of the desired surface area. In addition to sanitizing tool or cart handle, the device allows the user to direct the sanitizing spray into their hands to eliminate or minimize the transfer or spread of communicable pathogens. The fluid reservoir may be refillable or, alternatively, the fluid reservoir may be disposable and replaceable when the fluid is depleted.

Abstract: A sterilization container for sterilizing at least one surgical instrument. The container includes at least one sensor for measuring an environmental characteristic of the container during the sterilization of the instrument. The measure of the environmental characteristic is supplied to a processor. The processor compares the measurement of the container environment to a validated measurement for the sterilization process. If the measured environmental characteristic is at least equal to the validated sterilization process measurement, the processor presents an indication that the surgical instruments was properly sterilized.

Abstract: Diminishing gel compositions are disclosed and described. A diminishing gel composition can include a polymer matrix, a gel-diminishing agent, and a releasable active agent, such as an olfactory agent. The gel-diminishing agent can facilitate a visually noticeable or detectible gradual decrease in volume of the gel composition while in use. The releasable active agent can be released from the gel composition at a rate and amount that is sufficient to produce a desired result, such as an effective olfactory event.

Abstract: A controlled diffuser device can include a cover, a louver panel, a substrate member, and a base is disclosed. A cover and a base can be configured to affix to each other to sandwich a substrate member and a louver panel while enabling a substrate member and louver panel to slidably engage a base upper surface. A substrate member may comprise a material that changes in a physical dimension as it diffuses aromatic components. Because of static securement and slidable engagement configurations, a louver panel operatively shutters apertures of a cover to selectively moderate varying degrees of exposure of a substrate member as a substrate member changes in a physical dimension. Other embodiments may include a base configured to receive a substrate member and have a cover placed over top. As the substrate changed in physical dimension, the cover can be caused to move relative to the base.

Abstract: A scent diffuser (e.g., air freshener) configured to automatically circulate fragrant air throughout a surrounding environment comprises a powered air circulator configured for circulating air and a fragrance composition throughout the surrounding environment, and a solar cell positioned within a support face of the air circulator. The support face is configured to secure the scent diffuser relative to a support surface and has an open portion configured to allow light to contact the solar cell. The air circulator may comprise a centrifugal fan positioned within the housing and configured to draw air through intake apertures in sidewalls of the housing and to exhaust air and fragrance through an outflow aperture of the housing.

Abstract: A refill for dispensing a volatile material includes a bottle having a body defined by at least one sidewall and a neck extending outwardly from the at least one sidewall. The neck includes a rim at an upper end thereof, the neck being defined by an inner surface, a top surface, and an outer surface. The refill further includes a plug and a wick having a first end positioned within the bottle and a second end extending out of the bottle, the wick further defining a longitudinal axis. The plug is coupled to the neck of the bottle, the plug retaining the wick within the bottle. At least a portion of the inner surface of the rim is tapered at an angle of between about 2 and about 9 degrees with respect to the longitudinal axis.

Abstract: A removable replaceable cartridge for use with a liquid diffusing device. The cartridge includes a venturi, a conduit extending to the venturi, a mixing area and an outlet path for atomizing and dispersing a liquid within the cartridge. A diffusion device including a removable replaceable cartridge received within a housing. The housing includes a source of compressed gas which is directed into the cartridge. A venturi head with a unitary body for use with a diffusion device.

Abstract: Systems and methods for managing scent in an environment include receiving data from sensors disposed in an environment regarding an indication that a service is being delivered in the environment and identifying remote atomizing scent diffusion devices disposed in the environment, wherein each scent diffusion device comprises a communications facility that enables transmitting signals to and receiving signals from the remote computer. Based on the indication, an electronic data structure is created defining a physical operational state of the scent diffusion devices, including data specifying at least one of a production of a scent that is intended to be a complement to the service, a fan speed of a fan in the diffusion device that moves particles carrying a scent, and a voltage of a pump of the diffusion device. The diffusion devices are caused to implement the at least one defined operational state.

Abstract: Systems and methods for managing scent in an environment include disposing scent diffusion devices within the environment, wherein the diffusion devices comprise a communications facility that enables transmitting signals to and receiving signals from a non-fragrance dispensing, wide-area network gateway device that receives communication and control functions from a remote computer for distribution to the plurality of scent diffusion devices. A sensor in the environment transmits sensor data to the remote computer. A scent parameter for scenting the environment is received at the remote computer. Diffusion of a liquid from the scent diffusion devices is controlled by the network gateway device the to achieve the scent parameter, wherein controlling includes setting or adjusting an operation parameter of one or more of the scent diffusion devices in response to the sensor data.

Abstract: A reservoir containing an essential oil feeds to an eductor injecting a jet forming a plume of air entraining oil droplets. A series of drift chambers act as velocity reducers to alternately slow the flow droplets with entry, and then reaccelerate them upon exit through an exit channel. A micro cyclone separator operates between at least two of the drift chambers, exposing the flow to circumferential direction and centripetal acceleration driving comparatively larger droplets out of the flow away from comparatively finer droplets sufficiently small to remain with the flow of air. Separation of comparatively larger droplets, effectively eliminates “spitting” of liquids that might or rapid drift onto surrounding surfaces.

Abstract: Embodiments of the invention include a vessel having an opening and a detachable cover for covering the opening. The cover includes a semiconductor device with an active layer disposed between an n-type region and a p-type region. The active layer emits radiation having a peak wavelength in a UV range. The cover also includes a sensor for detecting whether the cover is covering the opening.

Abstract: Polymeric compositions are described comprising a biocompatible polymer including a biodegradable linkage to a visualization agent and a non-physiological pH solution; wherein the biocompatible polymer is soluble in the non-physiological pH solution and insoluble at a physiological pH. Methods of forming the solutions and polymers are disclosed as well as methods of therapeutic use.

Abstract: The invention features biodegradable materials, and in vitro and in vivo methods of using such compositions to promote bone and soft tissue growth and healing.

Abstract: A process and apparatus for applying a needle lubricant to a syringe. The interface forces between the needle lubricant and the syringe at the tip of the needle are balanced by optimizing the flow rate of a positively pressurized gas that is delivered to the syringe. Such optimization prevents the formation of bubbles in the needle lubricant that is applied to the syringe, thereby providing a confluent, uniform and smooth lubricant coating on the exterior wall of the needle and prevents lubricant from contaminating inner portions of the syringe. The smooth and uniform lubricant coating may minimize dilation and glide forces and pain associated with the insertion of the needle into a patient's tissue. Additionally, a gas pulse may blow off the droplet of needle lubricant from the tip of the needle to further minimize dilation forces and associated patient pain.

Abstract: This invention is directed to a new method of mass-transfer/fabrication of micro-sized features/structures onto the inner diameter (ID) surface of a stent. This new approach is provided by technique of through mask electrical micro-machining. One embodiment discloses an application of electrical micro-machining to the ID of a stent using a customized electrode configured specifically for machining micro-sized features/structures.

Abstract: Methods and systems are provided for a sub-atmospheric wound-care (SAWS) system for treating an open wound. The SAWS system includes a regulated vacuum source for developing a negative pressure, a flow rate meter configured to measure a flow rate of liquid removed from the wound, a primary pressure regulating sensor located proximate the wound for directly measuring the negative pressure at the wound, a backup pressure regulating sensor located vacuum tube, a porous dressing suitable to be sealed airtight which is positioned within a wound interface chamber, a collection canister configured to collect said liquid removed from the wound, and an adapter configured to use wall suction a primary regulated vacuum source.

Abstract: A pressure controller for a phlegm sucking device includes a seat body, a press element and a control valve. The seat body has a containing space, a gas inlet tube and a gas outlet tube interconnected with each other. The control valve is disposed in the containing space. An upper end and a bottom end of the control valve abut the press element and an upper portion and a bottom of the seat body respectively for blocking or allowing communication between the gas inlet tube and the gas outlet tube. The control valve includes a plastic restoring element. When the plastic restoring element is deformed to have a decreased height, the plastic restoring element allows the control valve to move and provide a resilience. The control valve blocks the communication between the gas inlet tube and the gas outlet tube when the plastic restoring element is not deformed.